# Tvardi Therapeutics (TVRD) — Analyst Forecast

TVRD · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tvrd/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 7 | 1 | 1 | 9 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 8, 2026 | LUCID CAPITAL MARKETS | Initiated Coverage | Buy | $14.00 |
| Jul 30, 2026 | BTIG | Maintained | Buy | $5.00 |
| Jul 8, 2026 | Raymond James | Upgraded | Market Perform → Outperform | $10.00 |
| Jul 7, 2026 | BTIG | Maintained | Buy | $15.00 |
| Jun 8, 2026 | HC Wainwright & Co. | Initiated Coverage | Buy | $9.00 |
| Apr 20, 2026 | Barclays | Downgraded | Equal-Weight → Underweight | $3.00 |
| Apr 1, 2026 | Piper Sandler | Maintained | Neutral | $3.00 |
| Apr 1, 2026 | Barclays | Maintained | Equal-Weight | $4.00 |
| Apr 1, 2026 | BTIG | Maintained | Buy | $15.00 |
| Oct 14, 2025 | Raymond James | Downgraded | Outperform → Market Perform | — |
| Oct 13, 2025 | BTIG | Maintained | Buy | $15.00 |
| Oct 13, 2025 | Barclays | Initiated Coverage | Overweight | $61.00 |
| Jul 14, 2025 | Raymond James | Initiated Coverage | Outperform | $62.00 |
| Jul 11, 2025 | Cantor Fitzgerald | Initiated Coverage | Overweight | $52.00 |
| Jun 12, 2025 | Piper Sandler | Initiated Coverage | Overweight | $78.00 |
| May 21, 2025 | Oppenheimer | Initiated Coverage | Outperform | $65.00 |
| Apr 28, 2025 | Jones Trading | Initiated Coverage | Buy | $39.00 |
| Jun 13, 2024 | Needham | Downgraded | Buy → Hold | — |
| Jun 13, 2024 | HC Wainwright & Co. | Downgraded | Buy → Neutral | — |
| Jun 13, 2024 | Canaccord Genuity | Downgraded | Buy → Hold | $1.00 |

## Frequently Asked Questions

### Is TVRD a buy, sell, or hold?

Analysts covering Tvardi Therapeutics currently average a Buy rating: 7 buy, 1 hold and 1 sell, from 9 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on TVRD?

On Sep 8, 2026, LUCID CAPITAL MARKETS initiated coverage of Tvardi Therapeutics at Buy with a price target of $14.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).